Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec:22 Suppl 3:S630-7.
doi: 10.1245/s10434-015-4807-6. Epub 2015 Aug 14.

Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy

Jeong Eun Kim  1 , Yong Sang Hong  1 , Hwa Jung Kim  2 , Kyu-Pyo Kim  1 , Jae-Lyun Lee  1 , Seong Joon Park  1 , Seok-Byung Lim  3 , In Ja Park  3 , Chan Wook Kim  3 , Yong Sik Yoon  3 , Chang Sik Yu  3 , Jin Cheon Kim  3 , Kim Ji Hoon  4 , Tae Won Kim  5
Affiliations

Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy

Jeong Eun Kim et al. Ann Surg Oncol. 2015 Dec.

Abstract

Background: Mismatch repair (MMR) status has been proposed, with some controversy, as a prognostic and predictive marker in stage II colon cancer. The aim of this study was to evaluate the association between MMR and survival in stage II colon cancer.

Methods: A total of 860 patients with curatively resected stage II colon cancer were selected for inclusion between January 2003 and December 2008. Tumors lacking expression of MLH1 and/or MSH2, as determined by immunohistochemistry, were classified as having deficient MMR (dMMR), whereas other tumors were classified as having proficient MMR (pMMR). Clinical risk (CR) factors were used to divide patients into high or standard CR groups.

Results: Of 860 patients, 14.7 % were dMMR, 42.4 % had ≥1 CR factors, and 85.8 % patients received adjuvant chemotherapy. MMR status did not affect disease-free survival (DFS; hazard ratio [HR] 1.191, p = 0.415) or overall survival (OS; HR 1.300, p = 0.344). Among CR factors, only pathologic T4 disease tended to associate with poor OS (HR 1.979, p = 0.071). Adjuvant chemotherapy was associated with better DFS (HR 0.393, p < 0.0001) in patients with pMMR tumors. However, in patients with dMMR tumors, adjuvant chemotherapy was not associated with DFS.

Conclusions: MMR status did not affect DFS or OS in patients with stage II colon cancer. In patients treated with adjuvant chemotherapy, dMMR was not associated with DFS and OS. However, adjuvant chemotherapy was associated with improved DFS in pMMR patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.
    Fountzilas E, Kotoula V, Pentheroudakis G, Manousou K, Polychronidou G, Vrettou E, Poulios C, Papadopoulou E, Raptou G, Pectasides E, Karayannopoulou G, Chrisafi S, Papakostas P, Makatsoris T, Varthalitis I, Psyrri A, Samantas E, Bobos M, Christodoulou C, Papadimitriou C, Nasioulas G, Pectasides D, Fountzilas G. Fountzilas E, et al. ESMO Open. 2019 Mar 12;4(2):e000474. doi: 10.1136/esmoopen-2018-000474. eCollection 2019. ESMO Open. 2019. PMID: 31231557 Free PMC article.
  • JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment.
    Cheng S, Li M, Li C, Dai Y, Zhuo J, Wang J, Qian J, Hao Z. Cheng S, et al. In Vitro Cell Dev Biol Anim. 2024 Apr;60(4):382-396. doi: 10.1007/s11626-024-00881-8. Epub 2024 Apr 16. In Vitro Cell Dev Biol Anim. 2024. PMID: 38625487
  • NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
    Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Benson AB, et al. J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021. J Natl Compr Canc Netw. 2018. PMID: 29632055 Free PMC article.
  • Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.
    Jin Z, Sinicrope FA. Jin Z, et al. Cancers (Basel). 2021 Jan 15;13(2):300. doi: 10.3390/cancers13020300. Cancers (Basel). 2021. PMID: 33467526 Free PMC article. Review.
  • Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
    Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Benson AB, et al. J Natl Compr Canc Netw. 2019 Sep 1;17(9):1109-1133. doi: 10.6004/jnccn.2019.0043. J Natl Compr Canc Netw. 2019. PMID: 31487687 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources